Product Overview Data Sheet Protocol
This vector is a constitutive mammalian expression vector designed to deliver exceptionally high levels of antibody expression. This circular vector features an enhanced, full-length CMV promoter and other expression elements that typically enable higher expression levels. It can be used in suspension-adapted cells, such as Expi293F™ and ExpiCHO™, for transient protein expression. Additionally, it can serve as a Geneticin®-selectable expression plasmid for engineering stable cell lines. The vector carries an ampicillin resistance gene.
Mouse IgM is the first antibody secreted by the adaptive immune system in response to a foreign antigen. Monomeric IgM is a heterotetramer of approximately 180 kDa. However, the secreted form of IgM exists predominantly in a pentameric configuration with a molecular weight greater than 900 kDa. The pentamer are connected at their Fc portions by a J, or joining chain (pFB-mIgJ).
Specifications of Antibody Expression Vector| Antibiotic Resistance | Ampicillin (AmpR) |
| Constitutive or Inducible System | Constitutive |
| Delivery Type | Transfection |
| Promoter | CMV |
| Product Type | Mammalian Expression Vector |
| Cloning Method | Restriction Enzyme (5’-AgeI; 3’-XhoI) or Homologous Assembly |
Contents & Storage
- 5.0 µg of pFB-CHIg-mM (pentamer) in Tris-EDTA buffer
- Store at -20°. Vectors are guaranteed stable for 12 months when properly stored.
Materials required for antibody generation and isotype switching
pFB-mIgJ with pFB-CLIg-mk or pFB-CLIg-ml1, pFB-CLIg-ml2 plasmids expressing the mouse kappa light chain or mouse lambda chain.
Vector usage
- Entire monoclonal mouse IgM antibody production: cloning your heavy/light chain variable regions in the cloning sites to preserve the integrity of the heavy/light chain constant region.
- Isotype switching: pFB-CHIg-mM (pentamer) with pFB-mIgJ and pFB-CLIg-mk or pFB-CLIg-ml1, pFB-CLIg-ml2 plasmids are designed to switch a monoclonal antibody from one isotype to another; therefore, maintaining the generated new antibodies with the same antigen affinity (epitopes) but with different effector functions (enhanced or reduced or even disabled ADCC and CDC).
